Health Care • Biotechnology: Pharmaceutical Preparations
$18.48 ▼ -0.09
(-0.48%)
MKT CAP: $602.7M • VOL: 168.9K
52W L $6 52W H $29
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$16
MEDIAN
$21
MEAN
$21
HIGH
$25
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NVCT TAPE
NVCT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $22.36 | $21.25 | 2025-02-14 | $16.82 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $23.28 | $21.81 | 2025-02-06 | $17.37 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $21.07 | $20.33 | 2025-01-29 | $17.74 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $18.85 | — | 2025-01-17 | $18.11 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $16.26 | $17.56 | 2025-01-09 | $16.45 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $21.99 | $19.22 | 2024-12-18 | $16.08 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $17.93 | $18.66 | 2024-12-04 | $17.19 | -4.3% | 48% | C |